News

October 8, 2017: TECHFIELDS BEGUN PHASE II CLINICAL TRIAL OF TF0023

Date:2018-02-09View: 23

Techfields has begun the Phase II clinical trial of a novel drug, TF0023, in 40 Sites in the US for the recovery of ischemic strokes. The study title is:

A Phase 2, Multicenter, Randomized, Double-blind (within dose), Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray versus Placebo in Functional Improvement of Patients with Ischemic Strokes